Related references
Note: Only part of the references are listed.Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice
Ruixin Sun et al.
MOLECULAR THERAPY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
Tyler R. McCaw et al.
CANCER MEDICINE (2021)
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer
Vijayalaxmi G. Gupta et al.
GYNECOLOGIC ONCOLOGY (2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
Shariska Petersen et al.
GYNECOLOGIC ONCOLOGY (2020)
Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer
Alyssa A. Hoover et al.
BMC CANCER (2020)
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj et al.
CANCER CELL (2019)
Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis
Meichen Yin et al.
ONCOTARGETS AND THERAPY (2019)
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
F. Zhang et al.
NATURE COMMUNICATIONS (2019)
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2018)
Prognosis of ovarian cancer is associated with effector memory CD8(+) T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells
Sonja Lieber et al.
ONCOIMMUNOLOGY (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
Vijayalaxmi Gupta et al.
CANCERS (2018)
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy
David Briere et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Thomas Worzfeld et al.
FRONTIERS IN ONCOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2016)
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek et al.
GYNECOLOGIC ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer
Andrew J. Wilson et al.
MOLECULAR CANCER (2015)
Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
Andrew J. Wilson et al.
JOURNAL OF OVARIAN RESEARCH (2015)
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
Andrew J. Wilson et al.
ONCOTARGET (2015)
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
Panagiotis A. Konstantinopoulos et al.
GYNECOLOGIC ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013
Jing Wang et al.
NUCLEIC ACIDS RESEARCH (2013)
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Dariush Etemadmoghadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model
Andrew J. Wilson et al.
JOURNAL OF OVARIAN RESEARCH (2013)
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
Daehwan Kim et al.
GENOME BIOLOGY (2013)
VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5
Daniel Herr et al.
GYNECOLOGIC ONCOLOGY (2012)
Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
Li Shen et al.
PLOS ONE (2012)
Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
Andrew J. Wilson et al.
JOURNAL OF OVARIAN RESEARCH (2012)
The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells
Andrew J. Wilson et al.
CANCER BIOLOGY & THERAPY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21
Deok-Soo Son et al.
CANCER BIOLOGY & THERAPY (2010)
Re-educating tumor-associated macrophages by targeting NF-κB
Thorsten Hagemann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma
Filiz Bolat et al.
PATHOLOGY RESEARCH AND PRACTICE (2008)
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth - Implications for therapy
Dineo Khabele et al.
CANCER BIOLOGY & THERAPY (2007)
Development of a syngeneic mouse model for events related to ovarian cancer
KF Roby et al.
CARCINOGENESIS (2000)
Share Paper
